Steroid_NN
dose_NN
sparing_NN
:_:
pharmacodynamic_JJ
responses_NNS
to_TO
single_JJ
versus_CC
divided_JJ
doses_NNS
of_IN
methylprednisolone_NN
in_IN
man_NN
._.

Inhibitory_JJ
drug_NN
interactions_NNS
affecting_VBG
the_DT
metabolism_NN
of_IN
methylprednisolone_NN
-LRB-_-LRB-
MP_NN
-RRB-_-RRB-
may_MD
produce_VB
either_CC
steroid_NN
sparing_NN
or_CC
adverse_JJ
effects_NNS
partly_RB
by_IN
increasing_VBG
the_DT
exposure_NN
time_NN
to_TO
the_DT
steroid_NN
._.

This_DT
phenomenon_NN
can_MD
be_VB
mimicked_VBN
by_IN
administering_VBG
MP_NN
in_IN
divided_JJ
doses_NNS
._.

Two_CD
types_NNS
of_IN
responses_NNS
were_VBD
compared_VBN
after_IN
a_DT
single_JJ
MP_NN
dose_NN
-LRB-_-LRB-
40_CD
mg_NN
bolus_NN
-RRB-_-RRB-
and_CC
a_DT
divided_JJ
regimen_NN
-LRB-_-LRB-
20_CD
mg_NN
bolus_NN
and_CC
a_DT
5_CD
mg_NN
bolus_NN
8_CD
hours_NNS
later_RB
-RRB-_-RRB-
in_IN
six_CD
healthy_JJ
male_JJ
volunteers_NNS
._.

The_DT
suppression_NN
of_IN
basophils_NNS
measured_VBN
as_IN
whole_JJ
blood_NN
histamine_NN
and_CC
plasma_NN
cortisol_NN
concentrations_NNS
was_VBD
assessed_VBN
during_IN
32_CD
hours_NNS
._.

The_DT
37.5_CD
%_NN
reduction_NN
in_IN
dose_NN
produced_VBD
a_DT
23_CD
%_NN
overall_RB
decreased_VBN
blood_NN
histamine_NN
response_NN
._.

A_DT
pharmacodynamic_JJ
model_NN
for_IN
basophil_NN
cell_NN
distribution_NN
to_TO
and_CC
from_IN
an_DT
extravascular_JJ
compartment_NN
describes_VBZ
the_DT
effects_NNS
of_IN
MP_NN
after_IN
both_DT
regimens_NNS
._.

A_DT
slower_JJR
initial_JJ
decline_NN
in_IN
blood_NN
histamine_NN
after_IN
the_DT
divided_JJ
regimen_NN
may_MD
be_VB
related_JJ
to_TO
incomplete_JJ
suppression_NN
of_IN
basophil_NN
cell_NN
return_NN
to_TO
blood_NN
._.

The_DT
50_CD
%_NN
inhibitory_JJ
concentrations_NNS
of_IN
MP_NN
of_IN
about_RB
5_CD
ng\/ml_NN
were_VBD
similar_JJ
for_IN
both_DT
regimens_NNS
._.

The_DT
decline_NN
and_CC
return_NN
of_IN
cortisol_NN
concentrations_NNS
were_VBD
similar_JJ
between_IN
MP_NN
treatments_NNS
with_IN
suppression_NN
continuing_VBG
for_IN
24_CD
hours_NNS
._.

The_DT
50_CD
%_NN
inhibitory_JJ
concentrations_NNS
of_IN
MP_NN
values_NNS
for_IN
adrenal_JJ
suppression_NN
were_VBD
about_RB
1_CD
ng\/ml_NN
._.

Pharmacodynamic_JJ
modeling_NN
is_VBZ
useful_JJ
in_IN
quantitating_VBG
corticosteroid_NN
responses_NNS
and_CC
generally_RB
predicted_VBD
the_DT
``_JJ
dose-sparing_JJ
''_NN
effects_NNS
that_WDT
were_VBD
achieved_VBN
by_IN
prolonging_VBG
MP_NN
plasma_NN
concentrations_NNS
._.

This_DT
study_NN
supports_VBZ
previous_JJ
clinical_JJ
observations_NNS
that_IN
patients_NNS
may_MD
require_VB
morning_NN
through_IN
evening_NN
exposure_NN
to_TO
MP_NN
to_TO
optimize_VB
efficacy_NN
while_IN
adrenal_JJ
suppression_NN
is_VBZ
being_VBG
minimized_VBN
._.

